H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Nuvectis Pharma (NVCT – Research Report) today and set a price target of $15.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Joseph Pantginis’s rating is based on several promising developments surrounding Nuvectis Pharma’s NXP900. The company presented compelling preclinical data at AACR ’25, highlighting NXP900’s potential in treating solid tumors, particularly non-small cell lung cancer (NSCLC). The data demonstrated that NXP900 effectively inhibits tumor growth and shows synergistic effects when combined with other cancer treatments, such as alectinib, lorlatinib, and osimertinib, especially in cases resistant to these therapies.
NXP900 is also undergoing clinical evaluation as a monotherapy in a Phase 1a/b study targeting YES1/SRC-driven tumors. The initial findings from this study indicate a favorable safety profile and predictable pharmacokinetics and pharmacodynamics. With no dose-limiting toxicity identified up to 250 mg/day, the study supports further clinical exploration. These factors contribute to Pantginis’s optimism about Nuvectis Pharma’s future prospects, leading to his Buy rating.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NVCT in relation to earlier this year.